


Evidence-Based Medicine

A Compendium of Studies



Cook Spectrum®
TECHNOLOGY



www.cookmedical.com

Unmatched evidence in the effort to prevent CRBSIs

The science and efficacy of minocycline+rifampin catheters.

The evidence examining and supporting Cook Spectrum® technology is vast, but this bibliography of studies organizes the research into manageable sections that are easy to understand and quickly referenced.

Spectrum's Efficacy

- 1. A comparison of two antimicrobial-impregnated central venous catheters.**
Darouiche RO, Raad II, Heard SO, et al.
New England Journal of Medicine. 1999;340(1):1-8.
nejm.org/doi/full/10.1056/NEJM199901073400101
- 2. Antimicrobial central venous catheters in adults: a systematic review and meta-analysis.**
Casey AL, Mermel LA, Nightingale P, et al.
The Lancet Infectious Diseases. 2008;8(12):763-776.
ncbi.nlm.nih.gov/pubmed/19022192
- 3. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units.**
Ramritu P, Halton K, Collignon P, et al.
American Journal of Infection Control. 2008;36(2):104-117.
ncbi.nlm.nih.gov/pubmed/18313512
- 4. The evolving technology of venous access.**
Wenzel RP, Edmond MB.
New England Journal of Medicine. 1999;340(1):48-50.
ncbi.nlm.nih.gov/pubmed/9878645
- 5. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial.**
Raad I, Darouiche R, Dupuis J, et al.
Annals of Internal Medicine. 1997;127(4):267-274.
annals.org/article.aspx?articleid=710759
- 6. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters.**
Marik PE, Abraham G, Careau P, et al.
Critical Care Medicine. 1999;27(6):1128-1131.
ncbi.nlm.nih.gov/pubmed/10397217
- 7. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials.**
Falagas ME, Fragoulis K, Bliziotis IA, et al.
Journal of Antimicrobial Chemotherapy. 2007;59(3):359-369.
jac.oxfordjournals.org/content/59/3/359.full
- 8. Effect of chlorhexidine/silver sulfadiazine-impregnated central venous catheters in an intensive care unit with a low blood stream infection rate after implementation of an educational program: a before-after trial.**
Schuerer DJ, Zack JE, Thomas J, et al.
Surgical Infections. 2007;8(4):445-454.
ncbi.nlm.nih.gov/pubmed/17883361
- 9. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters.**
Hanna H, Bahna P, Reitzel R, et al.
Antimicrobial Agents and Chemotherapy. 2006;50(10):3283-3288.
ncbi.nlm.nih.gov/pmc/articles/PMC1610097

Spectrum and Science

10. **Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin.**
Raad I, Darouiche RO, Hachem R, et al.
Critical Care Medicine. 1998;26(2):219-224.
ncbi.nlm.nih.gov/pubmed/9468157
11. **Novel approach using antimicrobial catheters to improve the management of central line-associated bloodstream infections in cancer patients.**
Chaftari A, Kassis C, El Issa H, et al.
Cancer. 2011;117(11):2551-2558.
onlinelibrary.wiley.com/doi/10.1002/cncr.25807/full
12. **The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin.**
Raad I, Darouiche R, Hachem R, et al.
The Journal of Infectious Diseases. 1996;173(2):418-424.
jstor.org/stable/30126138
13. **Antibiotics and prevention of microbial colonization of catheters.**
Raad I, Darouiche R, Hachem R, et al.
Antimicrobial Agents and Chemotherapy. 1995;39(11):2397-2400.
ncbi.nlm.nih.gov/pmc/articles/PMC162954
14. **Antibiotic susceptibility of staphylococcal isolates from patients with vascular catheter-related bacteremia: potential role of the combination of minocycline and rifampin.**
Darouiche RO, Raad II, Bodey GP, et al.
International Journal of Antimicrobial Agents. 1995;6(1):31-36.
ncbi.nlm.nih.gov/pubmed/18611682
15. **Anti-adherence activity and antimicrobial durability of anti-infective-coated catheters against multidrug-resistant bacteria.**
Raad I, Reitzel R, Jiang Y, et al.
Journal of Antimicrobial Chemotherapy. 2008;62(4):746-750.
jac.oxfordjournals.org/content/62/4/746
16. **Effectiveness of impregnated central venous catheters for catheter related blood stream infection: a systematic review.**
Gilbert RE, Harden M.
Current Opinion in Infectious Diseases. 2008;21(3):235-245.
ncbi.nlm.nih.gov/pubmed/18448967
17. **The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review.**
Hockenhull JC, Dwan KM, Smith GW, et al.
Critical Care Medicine. 2009;37(2):702-712.
ncbi.nlm.nih.gov/pubmed/19114884

Spectrum's Cost Effectiveness

18. **New choices for central venous catheters: potential financial implications.**
Shorr AF, Humphreys CW, Helman DL.
Chest. 2003;124(1):275-284.
ncbi.nlm.nih.gov/pubmed/12853534
19. **Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use.**
Marciante KD, Veenstra DL, Lipsky BA, et al.
American Journal of Infection Control. 2003;31(1):1-8.
ncbi.nlm.nih.gov/pubmed/12548250
20. **Making Health Care Safer: A Critical Analysis of Patient Safety Practices.**
Shojania KG, Duncan BW, McDonald KM, et al.
Evidence Report/Technology Assessment Summary. 2001;(43):1-12.
ncbi.nlm.nih.gov/pubmed/11510252
21. **Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients.**
Hanna HA, Raad II, Hackett B, et al.
Chest. 2003;124(3):1030-1038.
ncbi.nlm.nih.gov/pubmed/12970034
22. **Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital.**
Warren DK, Quadir WW, Hollenbeak CS, et al.
Critical Care Medicine. 2006;34(8):2084-2089.
ncbi.nlm.nih.gov/pubmed/16763511
23. **Evidence that prevention makes cents: costs of catheter-associated bloodstream infections in the intensive care unit.**
Cosgrove SE.
Critical Care Medicine. 2006;34(8):2243-2244.
ncbi.nlm.nih.gov/pubmed/16883193

Spectrum's Antibiotic Resistance

24. **Comparison of an untreated vs. silver/chlorhexidine vs. rifampin/minocycline central venous catheter in reducing catheter-related bloodstream infections.**
Brooks K, Dauenhauer S, Nelson M.
Abstract presented at: APIC 28th Annual Educational Conference and International Meeting; June 10-14, 2001; Seattle, WA.
No online source.
25. **Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance.**
Chatzinikolaou I, Hanna H, Graviss L, et al.
Infection Control and Hospital Epidemiology. 2003;24(12):961-963.
ncbi.nlm.nih.gov/pubmed/14700414

26. **New technology for reducing infection and resistance in the ICU.**
Crnich CJ, Maki DG.
The Journal of Critical Illness. 2002;17:48-51.
business.highbeam.com/4312/article-1G1-83373440/new-technology-reducing-infection-and-resistance-icu
27. **Clinical effectiveness and risk of emerging resistance associated with prolonged use of antibiotic-impregnated catheters: more than 0.5 million catheter days and 7 years of clinical experience.**
Ramos ER, Reitzel R, Jiang Y, et al.
Critical Care Medicine. 2011;39(2):245-251.
ncbi.nlm.nih.gov/pubmed/21057308

Spectrum and Burn Patients

28. **Vancomycin-resistant organisms on a burn unit.**
Still J, Law E, Friedman B, et al.
Southern Medical Journal. 2001;94(8):810-812.
ncbi.nlm.nih.gov/pubmed/11549193
29. **The long-term effect of antibiotic-impregnated catheters on bloodstream infection rate in a PICU [APIC Abstract].**
Gilliam C, Honeycutt M, Schutze G, et al.
American Journal of Infection Control. 2004;32(3):E36.
[ajicjournal.org/article/S0196-6553\(04\)00156-7/abstract](http://ajicjournal.org/article/S0196-6553(04)00156-7/abstract)

Spectrum and Pediatric Patients

30. **Reduction of bloodstream infections associated with catheters in paediatric intensive care unit: stepwise approach.**
Bhutta A, Gilliam C, Honeycutt M, et al.
British Medical Journal. 2007;334(7589):362-365.
ncbi.nlm.nih.gov/pubmed/17303886
31. **Use of antibiotic-coated central venous catheters in critically ill children.**
Immergluck L, Hayani K, Starosta D, et al.
Paper presented at: 38th Annual Meeting of the Infectious Disease Society of America. September, 2000.
No online source.

Spectrum and Long-Term Silicone

32. **Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial.**
Darouiche RO, Berger DH, Khardori N, et al.
Annals of Surgery. 2005;242(2):193-200.
ncbi.nlm.nih.gov/pmc/articles/PMC1357724
33. **Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial.**
Hanna H, Benjamin R, Chatzinikolaou I, et al.
Journal of Clinical Oncology. 2004;22(15):3163-3171.
ncbi.nlm.nih.gov/pubmed/15284269



Customer Service Centers

EMEA: EDI - www.cookmedical.com/edi.do

Distributors: +353 61239240, ssc.distributors@cookmedical.com

Austria: +43 179567121, oe.orders@cookmedical.com

Belgium: +32 27001633, be.orders@cookmedical.com

Denmark: +45 38487607, da.orders@cookmedical.com

Finland: +358 972519996, fi.orders@cookmedical.com

France: +33 171230269, fr.orders@cookmedical.com

Germany: +49 6950072804, de.orders@cookmedical.com

Hungary: +36 17779199, hu.orders@cookmedical.com

Ireland: +353 61239252, ie.orders@cookmedical.com

Italy: +39 0269682853, it.orders@cookmedical.com

Netherlands: +31 202013367, nl.orders@cookmedical.com

Norway: +47 23162968, no.orders@cookmedical.com

Spain: +34 912702691, es.orders@cookmedical.com

Sweden: +46 858769468, se.orders@cookmedical.com

Switzerland - French: +41 448009609, fr.orders@cookmedical.com

Switzerland - Italian: +41 448009609, it.orders@cookmedical.com

Switzerland - German: +41 448009609, de.orders@cookmedical.com

United Kingdom: +44 2073654183, uk.orders@cookmedical.com

www.cookmedical.com

Americas: EDI - www.cookmedical.com/edi.do

Phone: +1 812.339.2235, 800.457.4500, Fax: 800.554.8335

E-mail: orders@cookmedical.com

Australia:

Phone: +61 738411188, 1800777222, Fax: +61 738411288, 1800077283

E-mail: cau.custserv@cookmedical.com